Gilead Exercises its Options with Arcus for its Three Clinical-Stage Programs to Treat Cancers

Shots: Gilead has exercised its options to 3 programs in Arcus’s portfolio, including both anti-TIGIT molecules, domvanalimab & AB308 along with etrumadenant & quemliclustat & will hold exclusive rights outside the US Arcus to receive $725M as option fees along with royalties & the transaction is expected to close at the end of 2021. Both …

Gilead Exercises its Options with Arcus for its Three Clinical-Stage Programs to Treat Cancers Read More »